Protalix BioTherapeutics (NYSE:PLX) Cut to “Buy” at StockNews.com

StockNews.com cut shares of Protalix BioTherapeutics (NYSE:PLX) from a strong-buy rating to a buy rating in a report published on Thursday morning.

Separately, HC Wainwright boosted their price objective on shares of Protalix BioTherapeutics from $10.00 to $15.00 and gave the company a “buy” rating in a research report on Monday, February 3rd.

Protalix BioTherapeutics Price Performance

Shares of NYSE PLX opened at $2.49 on Thursday. Protalix BioTherapeutics has a one year low of $0.82 and a one year high of $2.76. The firm’s 50 day simple moving average is $2.40 and its two-hundred day simple moving average is $1.76. The stock has a market capitalization of $194.30 million, a P/E ratio of -19.15 and a beta of 0.72.

Hedge Funds Weigh In On Protalix BioTherapeutics

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Sanctuary Advisors LLC purchased a new stake in Protalix BioTherapeutics in the 3rd quarter worth approximately $38,000. Y Intercept Hong Kong Ltd purchased a new stake in Protalix BioTherapeutics during the 4th quarter valued at approximately $35,000. GSA Capital Partners LLP grew its holdings in Protalix BioTherapeutics by 8.5% during the 3rd quarter. GSA Capital Partners LLP now owns 435,213 shares of the company’s stock valued at $444,000 after buying an additional 33,969 shares in the last quarter. PFG Investments LLC purchased a new stake in Protalix BioTherapeutics during the 4th quarter valued at approximately $39,000. Finally, Virtu Financial LLC purchased a new stake in Protalix BioTherapeutics during the 3rd quarter valued at approximately $44,000. Institutional investors own 16.53% of the company’s stock.

Protalix BioTherapeutics Company Profile

Protalix BioTherapeutics, Inc, a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in the United States, Australia, Canada, Israel, Brazil, Russia, Turkey, and internationally.